GSK plc has reported that the FDA accepted its application on February 6, 2024, to extend its RSV vaccine Arexvy to adults aged 50-59 who are at increased risk for RSV disease, with a decision expected by June 7, 2024. This makes GSK the first to seek approval for this age group, supported by positive Phase III trial results.